Ipca Laboratories Ltd.

NSE: IPCALAB · Healthcare

₹1,941.80-0.40%06 Nov 2026

Ask the data

Instant answers about Ipca Laboratories Ltd. — computed from its filings, no language model

Market cap₹49,263 cr

Current price₹1,941.80

High / Low₹2,010 / ₹1,271

P/E35.1

P/B5.68

Book value₹342.1

ROE16.2%

ROCE21.8%

Debt / equity0.07

Dividend yield0.11%

EPS (TTM)₹55.28

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 7 periods

	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	4,649	5,420	5,830	6,244	7,705	8,940	9,646
EBITDA	907	1,544	1,309	927	1,321	1,726	1,979
Operating margin	19.5%	28.5%	22.5%	14.8%	17.1%	19.3%	20.5%
Interest	16	9	8	46	138	85	76
Depreciation	210	209	232	262	357	398	418
Profit before tax	747	1,389	1,136	745	843	1,131	1,573
Tax	135	240	224	253	313	344	381
Net profit	606	1,140	884	471	547	738	1,141
EPS ₹	47.77	90.11	34.85	18.58	21.57	29.08	44.98
Operating cash flow	—	—	856	806	945	1,321	1,142
Capex	—	—	479	494	411	776	652
Dividend paid	—	—	101	101	51	101	52
Total assets	5,260	6,068	7,639	8,626	11,101	11,761	12,370
Equity	3,627	4,702	5,492	5,842	6,332	6,948	8,064

Quarterly performance

last 30 quarters · ₹ crore

showing latest 8 of 30 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	1,078	1,284	1,213	1,074	1,534	1,361	1,410	1,115	1,566	1,544	1,430	1,289	1,586	1,601	1,546	1,512	1,588	2,034	2,053	2,033	2,093	2,355	2,245	2,247	2,309	2,556	2,392	2,388	2,788	2,910
Operating profit	199	266	274	168	588	360	367	229	417	366	308	219	269	261	216	181	308	321	331	322	393	441	463	429	416	545	533	484	670	673
Operating margin	18.4%	20.7%	22.6%	15.7%	38.3%	26.5%	26.0%	20.5%	26.6%	23.7%	21.5%	17.0%	17.0%	16.3%	14.0%	12.0%	19.4%	15.8%	16.1%	15.8%	18.8%	18.7%	20.6%	19.1%	18.0%	21.3%	22.3%	20.3%	24.0%	23.1%
Other income	20	15	18	14	12	15	15	20	21	18	13	15	22	36	31	36	45	39	22	19	21	26	20	26	33	28	20	94	25	25
Interest	5	4	4	4	3	2	2	2	2	1	1	3	7	9	11	18	31	44	33	29	24	23	17	22	19	20	18	20	12	13
Depreciation	46	50	51	64	51	52	54	52	56	57	59	61	62	64	67	70	69	90	100	98	99	100	98	100	100	103	108	107	111	115
Profit before tax	168	227	237	115	547	321	326	195	380	326	261	170	223	224	169	129	252	225	289	77	290	345	368	128	331	392	446	404	572	547
Tax	37	32	37	29	100	53	57	31	71	68	57	28	74	77	54	48	86	88	66	74	91	99	91	62	96	108	82	95	149	156
Net profit	130	193	198	86	446	267	265	161	307	250	197	130	143	-3	6	77	163	145	180	60	192	229	248	68	233	283	326	299	402	375
EPS ₹	10.24	15.32	15.63	6.57	35.27	21.08	21.09	12.71	24.18	19.73	7.76	5.13	5.64	5.67	4.25	3.02	6.42	5.72	7.09	2.35	7.58	9.05	9.78	2.67	9.19	11.14	12.86	11.79	15.84	14.79
Revenue YoY	—	—	—	—	42.3%	6.0%	16.2%	3.8%	2.0%	13.5%	1.5%	15.6%	1.3%	3.7%	8.1%	17.3%	0.1%	27.0%	32.8%	34.5%	31.8%	15.8%	9.4%	10.5%	10.3%	8.6%	6.6%	6.3%	20.8%	13.8%
Profit YoY	—	—	—	—	244.2%	38.3%	34.3%	87.6%	-31.3%	-6.3%	-25.8%	-19.3%	-53.3%	-101.1%	-96.8%	-41.2%	13.8%	—	2719.4%	-22.1%	18.1%	58.2%	37.9%	13.8%	21.3%	23.1%	31.5%	341.0%	72.3%	32.8%

Earlier results (standalone, Sep '07 – Mar '19)

₹ crore · from BSE, before the NSE XBRL filings begin

Ipca Laboratories Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†
Revenue	1,274	2,329	2,778	3,235	3,085	2,816	3,144	3,219	3,633
Operating profit	268	521	621	805	520	324	435	442	693
Operating margin	21.0%	22.4%	22.4%	24.9%	16.9%	11.5%	13.8%	13.7%	19.1%
Other income	2	13	19	21	36	23	22	40	55
Interest	54	102	31	25	26	—	23	24	18
Depreciation	39	65	84	101	177	170	171	174	172
Profit before tax	125	369	461	629	358	109	258	283	557
Tax	33	89	130	152	102	17	70	50	102
Net profit	91	280	331	477	256	91	188	233	455

Quarters

showing latest 8 of 45 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	JUN '10†	SEP '10†	DEC '10†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†
Revenue	300	282	254	295	348	313	318	359	430	396	418	518	466	530	624	615	561	634	771	701	672	806	847	833	750	936	781	741	628	758	749	684	625	842	885	751	666	713	864	859	783	854	998	948	834
Operating profit	73	62	37	60	83	71	54	72	102	90	71	118	91	95	158	151	117	142	179	158	142	171	235	217	182	231	135	121	34	82	89	89	63	129	128	110	68	22	149	161	110	114	173	232	175
Operating margin	24.2%	21.8%	14.4%	20.2%	23.9%	22.7%	16.9%	20.0%	23.7%	22.8%	17.0%	22.8%	19.5%	18.0%	25.3%	24.6%	20.8%	22.3%	23.2%	22.6%	21.2%	21.2%	27.7%	26.1%	24.3%	24.7%	17.3%	16.4%	5.4%	10.8%	11.9%	13.0%	10.2%	15.3%	14.5%	14.7%	10.2%	3.0%	17.2%	18.8%	14.0%	13.4%	17.3%	24.5%	20.9%
Other income	0	1	1	0	0	0	1	4	1	1	1	1	0	3	3	4	4	3	9	4	3	4	5	5	6	6	9	6	14	4	5	5	9	5	6	6	5	6	11	11	11	14	14	13	15
Interest	5	6	5	4	31	11	8	1	7	5	5	6	6	1	39	51	11	10	9	7	6	7	6	5	6	6	6	6	8	5	7	9	—	7	7	6	4	6	6	6	6	5	2	5	6
Depreciation	8	8	8	9	9	10	11	11	12	12	13	14	14	15	18	18	14	20	21	22	22	24	25	26	26	38	40	42	58	42	44	45	39	42	43	43	43	43	44	44	43	44	43	43	42
Profit before tax	60	48	25	29	44	30	21	64	83	72	51	128	83	83	104	86	95	56	165	115	126	96	169	189	174	196	89	69	5	27	20	39	22	77	92	64	26	-21	110	123	72	78	141	197	141
Tax	14	10	2	6	7	7	13	14	19	14	12	34	19	22	26	22	19	14	40	27	50	24	40	50	37	50	27	27	-3	8	8	16	-16	29	37	22	-19	-1	13	17	20	13	21	37	32
Net profit	45	38	23	24	37	23	8	50	64	58	39	94	64	62	78	64	77	43	125	88	75	72	129	139	137	145	61	42	8	19	12	23	38	48	55	41	44	-20	96	106	51	66	120	160	109
EPS ₹	18.17	15.28	9.04	9.42	14.55	9.24	3.15	19.93	25.61	23.35	3.10	7.51	5.10	4.91	6.20	5.09	6.08	3.41	9.92	6.97	5.98	5.69	10.26	11.02	10.86	11.53	4.86	3.29	0.62	1.50	0.92	1.84	2.99	3.77	4.35	3.28	3.52	-1.60	7.64	8.37	4.07	5.19	9.48	12.68	8.67
Revenue YoY	—	—	—	—	15.8%	11.2%	25.1%	21.6%	23.8%	26.3%	16.4%	20.5%	17.9%	26.8%	20.3%	31.8%	—	19.7%	23.7%	14.0%	19.7%	27.0%	9.8%	18.8%	11.6%	16.2%	-7.8%	-11.1%	-16.2%	-19.0%	-4.0%	-7.6%	-0.5%	11.1%	18.1%	9.7%	6.6%	-15.3%	-2.3%	14.4%	17.6%	19.8%	15.4%	10.3%	6.5%
Profit YoY	—	—	—	—	-19.6%	-39.5%	-65.1%	110.6%	75.0%	151.3%	-22.0%	47.2%	9.8%	58.8%	-17.1%	0.0%	—	-30.3%	60.5%	37.4%	-1.5%	67.0%	3.5%	58.3%	81.7%	102.7%	-52.6%	-70.1%	-94.3%	-87.0%	-80.9%	-44.2%	383.8%	151.8%	370.1%	78.5%	17.8%	-142.6%	75.6%	155.1%	15.6%	—	24.1%	51.7%	113.4%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 27 periods

	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	16.7%	25.4%	27.5%	29.4%	24.2%	21.3%	20.9%	19.5%	16.1%	13.1%	8.1%	4.8%	3.8%	4.2%	6.4%	9.2%	8.6%	9.1%	9.9%	10.9%	10.6%	11.2%	11.2%	12.3%	14.2%	16.2%	16.2%
ROCE	18.9%	28.2%	30.5%	32.7%	28.2%	24.8%	24.9%	23.6%	18.2%	15.8%	13.8%	12.6%	10.8%	11.6%	10.9%	12.6%	12.7%	13.1%	14.1%	14.9%	14.7%	15.2%	15.0%	15.9%	18.8%	21.5%	21.8%
Net margin	13.0%	18.1%	19.2%	19.8%	21.0%	18.4%	17.5%	16.2%	15.2%	12.3%	7.9%	4.6%	3.6%	3.9%	5.9%	7.9%	7.1%	7.0%	7.7%	8.4%	8.3%	8.5%	8.9%	9.6%	11.8%	12.9%	13.4%
EBITDA margin	19.5%	25.4%	26.8%	27.6%	28.5%	25.2%	24.5%	23.3%	22.5%	19.9%	17.9%	16.0%	14.8%	15.5%	15.4%	15.9%	16.6%	16.6%	17.4%	18.6%	19.3%	19.1%	19.8%	20.2%	20.5%	22.0%	22.5%
Debt / equity	0.11	0.11	0.11	0.11	0.05	0.05	0.05	0.05	0.14	0.14	0.12	0.12	0.25	0.25	0.32	0.32	0.22	0.22	0.17	0.17	0.19	0.19	0.16	0.16	0.09	0.09	0.07
Interest coverage	46.25	77.79	96.79	119.89	154.65	151.52	179.55	194.14	148.69	77.39	42.63	26.78	17.37	12.07	8.40	8.03	7.09	7.73	10.15	12.64	14.32	15.75	16.93	17.78	21.71	27.17	32.63
Asset turnover	0.88	0.97	0.99	1.02	0.89	0.90	0.93	0.93	0.76	0.77	0.75	0.76	0.72	0.72	0.59	0.63	0.69	0.74	0.75	0.76	0.76	0.78	0.76	0.78	0.78	0.82	0.80

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
Other equity / reserves	1,934	2,183	2,234	2,430	2,663	3,097	3,590	4,676	5,467	5,753	5,817	6,123	6,307	6,675	6,923	7,402	8,038	8,653
Total equity	1,960	2,208	2,259	2,455	2,689	3,122	3,627	4,702	5,492	5,778	5,842	6,149	6,332	6,700	6,948	7,427	8,064	8,678
Borrowings	438	829	669	529	473	351	414	252	791	720	1,458	1,953	1,388	1,156	1,302	1,205	704	626
Current liabilities	791	904	970	956	1,008	1,098	1,326	1,161	1,466	1,385	1,806	2,686	2,356	2,396	2,384	2,537	2,307	2,407
Non-current liabilities	459	700	663	548	421	315	292	192	604	654	905	1,137	1,019	910	986	859	539	552
Total assets	3,211	3,812	3,892	3,960	4,117	4,551	5,260	6,068	7,639	7,898	8,626	11,384	11,101	11,424	11,761	12,263	12,370	13,133
Property, plant & equipment	1,298	1,719	—	—	—	—	—	—	—	2,328	2,572	4,342	4,340	4,291	4,069	4,168	4,441	4,545
Capital work-in-progress	149	236	94	62	42	36	71	184	294	246	122	267	324	485	616	777	762	832
Investments	9	16	—	22	18	30	34	77	115	370	626	760	862	944	980	1,203	844	1,055
Inventories	848	927	837	882	881	1,072	1,323	1,595	1,858	1,823	1,743	2,452	2,471	2,518	2,560	2,516	2,731	2,938
Receivables	450	353	446	500	602	682	895	812	911	1,103	989	1,760	1,687	1,814	1,874	2,077	2,014	2,395
Cash & equivalents	76	125	169	29	149	281	58	166	275	387	1,258	434	209	256	167	213	437	207

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 12 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	522	468	709	282	341	501	1,090	856	806	945	1,321	1,142
Cash from investing	-369	-689	-218	-149	-135	-165	-521	-855	-725	-1,292	-870	-247
Cash from financing	-136	251	-462	-159	-130	-183	-306	427	507	-553	-283	-754
Capex	380	558	247	136	137	181	—	479	494	411	776	652
Free cash flow	143	-90	462	146	204	320	—	377	311	533	546	490
Dividends paid	—	—	—	—	—	—	—	101	101	51	101	52

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹4,545 cr35%

CWIP

₹832 cr6%

Investments

₹1,055 cr8%

Inventories

₹2,938 cr22%

Receivables

₹2,395 cr18%

Cash & equivalents

₹207 cr2%

Other assets

₹1,161 cr9%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Ipca Laboratories Ltd.	49,263	1,941.80	35.1	5.68	16.2%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+0.2%

6 months+24.5%

1 year+50.5%

3Y CAGR+25.4%

5Y CAGR+12.9%

10Y CAGR+21.0%

50-day avg₹1,945.54

200-day avg₹1,686.44

RSI (14)65

Compare Ipca Laboratories Ltd. with

Abbott India vs Ipca Laboratories Gland Pharma vs Ipca Laboratories Anthem Biosciences vs Ipca Laboratories Ipca Laboratories vs Glaxosmithkline Pharmaceuticals

FAQs

What is the share price of Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. (IPCALAB) closed at ₹1,941.80 on NSE on 06 Nov 2026.

What is the market cap of Ipca Laboratories Ltd.?

₹49,263 crore at the latest close.

What is the P/E ratio of Ipca Laboratories Ltd.?

35.1, on trailing-twelve-month earnings from its filings.

How fast is Ipca Laboratories Ltd. growing?

Ipca Laboratories Ltd.: revenue has compounded at 15.6% a year over three years; net profit at 34.3% a year. Latest-quarter revenue is up 13.8% year on year, profit up 32.8%.

How profitable is Ipca Laboratories Ltd.?

On a trailing-twelve-month basis return on equity is 16.2%, return on capital employed 21.8%, operating margin 22.5%, net margin 13.4%.

How much debt does Ipca Laboratories Ltd. have?

Ipca Laboratories Ltd. is lightly geared: debt to equity is 0.07 with borrowings of ₹626 cr against cash of ₹207 cr (balance sheet of 2026-09-30). Operating profit covers interest 32.6 times.

Financials parsed from Ipca Laboratories Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '19, annual from FY20, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.